| Code | CSB-RA010949MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Enlimomab, targeting intercellular adhesion molecule 1 (ICAM1), also known as CD54. ICAM1 is a cell surface glycoprotein that plays a critical role in immune cell adhesion and transmigration across the endothelium during inflammatory responses. It serves as a ligand for leukocyte integrins, particularly LFA-1, facilitating the recruitment of immune cells to sites of inflammation and injury. ICAM1 is constitutively expressed at low levels on endothelial cells and leukocytes but becomes significantly upregulated during inflammatory conditions. Elevated ICAM1 expression is associated with various pathological states, including ischemia-reperfusion injury, stroke, inflammatory bowel disease, rheumatoid arthritis, and certain malignancies where it contributes to tumor progression and metastasis.
Enlimomab is a murine IgG2a monoclonal antibody that was investigated in clinical trials for acute ischemic stroke, though it did not achieve regulatory approval for therapeutic use. This biosimilar antibody provides researchers with a valuable tool for investigating ICAM1-mediated cellular adhesion mechanisms, inflammatory processes, and immune cell trafficking in various disease models.
There are currently no reviews for this product.